Background
==========

Acute pulmonary embolism (PE) is a relatively common medical emergency and is a life-threatening condition \[[@b1-amjcaserep-20-748]\], with a three-month mortality rate of up to 10% \[[@b2-amjcaserep-20-748]\]. While the symptoms of PE are often non-specific, the most common presentation includes symptoms such as acute dyspnea, tachypnea, and hypoxemia, as at least one of these symptoms is present in 92% of patients with PE \[[@b3-amjcaserep-20-748],[@b4-amjcaserep-20-748]\].

Acute dyspnea is the most common presenting sign of PE, noted in approximately 50% of these patients. Tachycardia is another common presenting symptom of PE, noted in at least 25% of these patients. Furthermore, tachycardia is one of diagnostic criteria included in the Well's score, a validated tool for stratification of PE risk \[[@b5-amjcaserep-20-748],[@b6-amjcaserep-20-748]\]. However, PE may also present with atypical, non-specific symptoms including syncope, abdominal pain, cardiac arrhythmia, or seizure \[[@b1-amjcaserep-20-748],[@b7-amjcaserep-20-748]\]. The wide variation in presenting symptoms complicate ante-mortem PE diagnosis, with up to 84% of PE cases discovered only on autopsy \[[@b8-amjcaserep-20-748]\].

This report is of an atypical presentation of PE in a 92-year-old man who presented with symptomatic bradycardia.

Case Report
===========

A 92-year-old man presented with first-degree atrioventricular (AV) block. He had a history of hypertension that was controlled on medication, stroke, an asbestos-related lung disease with pleural calcification, rheumatoid arthritis, and deep venous thrombosis (DVT), three years before this presentation. His current medications included diltiazem 180 mg, and combined hydrochlorothiazide (25 mg) and triamterene (37.5 mg) for hypertension, and clopidogrel (75 mg) for the prevention of secondary stroke.

Before his recent presenting event, the patient was in his usual state of health and was ambulatory, but with significantly reduced mobility due to arthritis. On the morning of his presentation to the hospital, the patient experienced dizziness and weakness while getting dressed, fell back on his bed, and slid down onto the floor. There was no loss of consciousness, no seizure activity, and no urinary or fecal incontinence. When the emergency services arrived, the patient was lethargic with a normal sinus rhythm of 18 beats/min and first-degree atrioventricular (AV) block. After receiving two doses of intravenous atropine (0.5 mg), his sinus rate increased to 80 beats/min.

During examination in the emergency room, the patient denied chest pain, shortness of breath, or cough. His blood pressure was 136/90 mmHg, his pulse rate was 73 beats per minute (bpm), his respiratory rate was 16 breaths per minute, and his oxygen saturation was 95% on breathing room air. His cardiovascular, pulmonary, and neurological examinations were un-remarkable. There was no significant edema. Laboratory investigations were notable for a leukocytosis of 11.6×10^9^/L, serum creatinine of 1.5 mg/dl, troponin of 1.75 ng/mL, and pro-brain natriuretic peptide (pro-BNP) of 1829 pg/ml. An electrocardiogram (ECG) showed sinus bradycardia of 48 bpm with first-degree AV block ([Figure 1](#f1-amjcaserep-20-748){ref-type="fig"}).

The patient was admitted to the hospital under the care of the internal medicine service and was placed under close observation. A transthoracic echocardiogram (TTE) showed a dilated right ventricle (RV) with a hypokinetic free wall and preserved right RV apical function (McConnell's sign). The interventricular septum was displaced towards the left ventricle, consistent with RV pressure overload. Given the patient's previous history of DVT and findings consistent with acute RV strain, the patient was further evaluated for PE. Computed tomography angiography (CTA) was not undertaken due to renal impairment. However, a ventilation/perfusion (V/Q) scan was performed and showed a high probability of PE with the involvement of more than 50% of the pulmonary vasculature ([Figure 2](#f2-amjcaserep-20-748){ref-type="fig"}).

Duplex ultrasound examination of the lower extremities was performed to evaluate the source of the PE and showed acute occlusion of the left common femoral vein. As systemic administration of thrombolytic agents was contraindicated given the patient's age, history of multiple comorbidities and high risk of bleeding, the patient was started on a high dose infusion of unfractionated heparin and underwent catheter-directed thrombolysis. However, the patient's condition deteriorated due to progressive hypoxemia, and he died shortly afterward. Endotracheal intubation was not performed, as the patient had an advanced directive not to be resuscitated.

Discussion
==========

This report is of an unusual case of acute submassive pulmonary embolism (PE) presenting as symptomatic bradycardia. This patient lacked the typical signs and symptoms of PE. The definitive diagnostic evaluation for PE was undertaken after the discovery of a dilated right ventricle (RV) with evidence of RV strain and positive McConnell's sign. Despite not having pleuritic chest pain and shortness of breath, the patient suffered from reduced mobility and also had a history of treated deep venous thrombosis, both of which increased his risk of PE \[[@b9-amjcaserep-20-748]\]. The clinical risk of PE in this patient was intermediate, based on his Well's score, but the findings from his ventilation/perfusion (V/Q) scan indicated that he had an 88% chance of having a PE \[[@b10-amjcaserep-20-748]\]. Computed tomography angiography (CTA) was not performed in his case, as the patient had renal impairment.

This case report highlights the importance of recognizing that PE may present with a wide spectrum of manifestations, which range from lack of symptoms to sudden death \[[@b11-amjcaserep-20-748]\].

The diagnosis of acute PE continues to be difficult due to variability in the clinical picture at presentation. The atypical presentations of PE, as reported in the literature, are presented in [Table 1](#t1-amjcaserep-20-748){ref-type="table"}.

Large cohort clinical studies have shown that sinus bradycardia may be present in more than 2% of patients with PE, and 3.5% may have first-degree AV block at presentation \[[@b34-amjcaserep-20-748]\]. PE complicated by cardiogenic shock may present as syncope in 26% of patients \[[@b35-amjcaserep-20-748]\]. Patients with large, hemodynamically significant PE that results in syncope are expected to present with compensatory tachycardia \[[@b36-amjcaserep-20-748]\]. However, sinus tachycardia has been documented in only 30% of patients with an acute embolism of the pulmonary trunk and the main pulmonary arteries \[[@b37-amjcaserep-20-748]\]. It has been proposed that bradycardia in patients with PE may be related to vagal stimulation which lowers heart rate and causes concurrent atrioventricular (AV) block. It is presumed that RV dilation and pressure overload from PE lead to excess vagal stimulation \[[@b4-amjcaserep-20-748]\]. In the presented case report, bradycardia could also be a side effect of prolonged treatment with diltiazem. However, this patient had never experienced symptomatic bradycardia prior to the development of PE, and his baseline asymptomatic first-degree AV block was unchanged. The management of patients with PE presenting with bradycardia is not well described. In one case report, symptomatic bradycardia resolved following theophylline treatment \[[@b12-amjcaserep-20-748]\]. In this patient, symptomatic bradycardia resolved following intravenous administration of atropine.

Increased serum levels of troponin and pro-brain natriuretic peptide (pro-BNP) in patients with acute PE indicate RV strain and dysfunction and are associated with an increased risk of poor clinical outcome and increased mortality \[[@b13-amjcaserep-20-748]\]. The report of this case supports this association, as this patient had markedly raised serum levels of pro-BNP and troponin on hospital admission, and his echocardiogram showed severe right heart strain with impaired RV systolic function, which indicated a poor prognosis. These findings also altered the clinical management, as increased serum levels of cardiac biomarkers and the presence of RV strain on transthoracic echocardiography (TTE) in patients with submassive PE are indications for fibrinolysis, which can be administered systematically, or using catheter-directed thrombolysis, as in this case \[[@b38-amjcaserep-20-748],[@b39-amjcaserep-20-748]\].

Conclusions
===========

Pulmonary embolism (PE) presenting with sinus bradycardia is rare. However, PE should be considered in patients who have multiple risk factors for thromboembolism. Missing the diagnosis of PE can increase patient morbidity and mortality. Early diagnosis and appropriate treatment interventions are required to improve clinical outcome in patients with acute PE.
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![The electrocardiogram (ECG) demonstrates sinus bradycardia of 48 beats per minute (bpm) with first-degree atrioventricular (AV) block.](amjcaserep-20-748-g001){#f1-amjcaserep-20-748}

![The ventilation/perfusion (V/Q) scan shows a high probability of pulmonary embolism (PE) in both lungs. More than 50% of the pulmonary vasculature contains pulmonary thromboembolus. Perfusion defects are identified by arrows.](amjcaserep-20-748-g002){#f2-amjcaserep-20-748}

###### 

Case reports of atypical presentation of pulmonary embolism (PE), including the current case.

  **First Author**                                **Atypical presenting symptom/s**   **Age (years)**   **Gender**   **Diagnosis**   **Treatment**                                   **Outcome**            **No. of cases**
  ----------------------------------------------- ----------------------------------- ----------------- ------------ --------------- ----------------------------------------------- ---------------------- ------------------
  Alreshq et al.                                  Bradycardia                         92                M            V/Q scan        Catheter-directed thrombolysis                  Death                  1
  Catella et al. \[[@b12-amjcaserep-20-748]\]     Bradycardia + dyspnea               32                F            CTA             Anticoagulation + theophylline                  Survival               1
  Majidi et al. \[[@b4-amjcaserep-20-748]\]       Epigastric pain                     42                M            CTA             Heparin                                         Death                  1
  Amesquita et al. \[[@b13-amjcaserep-20-748]\]   Flank pain                          63                F            CTA             Heparin                                         Unknown                1
  Viswanath et al. \[[@b14-amjcaserep-20-748]\]   New atrial fibrillation             82                M            CTA             Heparin + warfarin                              Survival               1
  Amesquita et al. \[[@b13-amjcaserep-20-748]\]   Flank pain                          64                F            CTA             Unknown                                         Unknown                1
  Rehman et al. \[[@b15-amjcaserep-20-748]\]      RUQ + back pain                     53                M            CTA             Enoxparin + rivaroxaban                         Survival               1
  Migneault et al. \[[@b16-amjcaserep-20-748]\]   RUQ + back pain                     63                F            CTA             Tenecteplase + heparin                          Unknown                1
  Amesquita et al. \[[@b13-amjcaserep-20-748]\]   RUQ + flank pain                    52                M            CTA             Heparin                                         Unknown                1
  Gantner et al. \[[@b17-amjcaserep-20-748]\]     RUQ pain                            48                M            CTA             Heparin                                         Survival               1
  Fosmire et al. \[[@b18-amjcaserep-20-748]\]     RUQ pain                            34                F            CTA             Self-resolved                                   Survival               1
  Allou et al. \[[@b19-amjcaserep-20-748]\]       Seizure                             40                M            CTA             Thrombolysis                                    Death                  1
  Volz et al. \[[@b20-amjcaserep-20-748]\]        Seizure                             76                M            CTA             Enoxparin + warfarin                            Survival               1
  Shah et al. \[[@b21-amjcaserep-20-748]\]        Seizure                             20                F            Autopsy         Thrombolysis + heparin                          Death                  1
  Marine et al. \[[@b22-amjcaserep-20-748]\]      Seizure                             33                M            CTA             Thrombolysis + heparin + warfarin               Survival               1
  Marine et al. \[[@b22-amjcaserep-20-748]\]      Seizure                             34                F            CTA             Mechanical thrombolysis + urokinase + heparin   Survival               1
  Hashmani et al. \[[@b23-amjcaserep-20-748]\]    Seizure                             38                M            CTA             Alteplase + heparin                             Survival               1
  Lam et al. \[[@b24-amjcaserep-20-748]\]         Seizure                             46                M/F          Varied          Varying                                         70% (7/10) Mortality   10
  Kimura et al. \[[@b25-amjcaserep-20-748]\]      Seizure                             --                M/F          Varied          Varying                                         N/A                    (2/285)
  Baloch et al. \[[@b26-amjcaserep-20-748]\]      Syncope                             74                F            CTA             Catheter-directed thrombolysis + heparin        Survival               1
  Altinsoy et al. \[[@b7-amjcaserep-20-748]\]     Syncope                             60                N/A          Varied          Varying                                         N/A                    (23/179)
  Koutkia et al. \[[@b27-amjcaserep-20-748]\]     Syncope                             54                M/F          Varied          Varying                                         38% (8/21) Mortality   21
  Keller et al. \[[@b28-amjcaserep-20-748]\]      Syncope                             76                M/F          Varied          Varying                                         N/A                    (6792/293,640)
  Keller et al. \[[@b29-amjcaserep-20-748]\]      Syncope                             78.5              M/F          Varied          Varying                                         20% (2/10) mortality   (20/182)
  Misra et al. \[[@b30-amjcaserep-20-748]\]       Syncope + fever                     43                M            Autopsy         Unknown                                         Death                  1
  Meyer et al. \[[@b31-amjcaserep-20-748]\]       Syncope + seizure                   50                M            V/Q scan        Heparin                                         Death                  1
  Fred et al. \[[@b32-amjcaserep-20-748]\]        Syncope + seizure                   37                M            Autopsy         Thrombolysis                                    Death                  1
  Ronco et al. \[[@b33-amjcaserep-20-748]\]       Syncope + seizure                   7                 F            CTA             Thrombolysis + heparin                          Survival               1

RUQ -- right upper quadrant; M -- Male; F -- Female; V/Q -- ventilation/perfusion; CTA -- computed tomography angiography.
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